TVARDI THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
TVARDI THERAPEUTICS, INC. (TVRD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of -$82.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-31
- TVARDI THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was -$82.00K, a 428.00% decline from fiscal 2024.
- TVARDI THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $25.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | -$82.00K 10-K · filed 2026-03-31 |
| 2024-12-31 | $25.00K 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |